VitaNova Life Sciences (VNOV) Price to Sales (2022 - 2026)

VitaNova Life Sciences has disclosed Price to Sales across 5 years of filings, most recently posting 3.55 for Q3 2026.

• Price to Sales for Q3 2026 came in at 3.55, down 30.2% year-over-year; the trailing twelve-month figure through Jul 2026 was 3.55 (down 30.2% YoY), and the FY2026 annual result was 3.8, down 25.05% from the prior year.
• Price to Sales for Q3 2026 stood at 3.55, down from 3.8 in the prior quarter.
• Across five years, Price to Sales topped out at 2274.47 in Q3 2023 and bottomed at 3.55 in Q3 2026.
• Average Price to Sales over 5 years is 325.55, with a median of 38.42 recorded in 2024.
• The widest annual swing landed in 2023, when Price to Sales soared 1757.59%; it then plunged 99.13% in 2024.
• Year by year, Price to Sales stood at 352.28 in 2022, then jumped by 130.77% to 812.94 in 2023, then sank by 98.29% to 13.91 in 2024, then soared by 211.1% to 43.26 in 2025, then slumped by 91.8% to 3.55 in 2026.
• The last three Price to Sales figures came in at 3.55 (Q3 2026), 3.8 (Q2 2026), and 12.61 (Q1 2026), per Business Quant data.